SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001013594-19-000315
Filing Date
2019-04-02
Accepted
2019-04-02 17:12:10
Documents
3

Document Format Files

Seq Description Document Type Size
1 APRIL 2, 2019 novelion13da-040219.htm SC 13D/A 83311
2 BOARD LETTER novelionex992-040219.htm EX-99.2 1191
3 BOARD LETTER novelionex992-040219.pdf EX-99.2 96759
  Complete submission text file 0001013594-19-000315.txt   219939
Mailing Address C/O NORTON ROSE FULBRIGHT 1800 - 510 WEST GEORGIA STREET VANCOUVER A1 V6B 0M3
Business Address C/O NORTON ROSE FULBRIGHT 1800 - 510 WEST GEORGIA STREET VANCOUVER A1 V6B 0M3 (877) 764-3131
NOVELION THERAPEUTICS INC. (Subject) CIK: 0000827809 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-43381 | Film No.: 19726192
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O WHITEFORT CAPITAL MANAGEMENT, LP 641 LEXINGTON AVENUE, SUITE 1530 NEW YORK NY 10022
Business Address C/O WHITEFORT CAPITAL MANAGEMENT, LP 641 LEXINGTON AVENUE, SUITE 1530 NEW YORK NY 10022 (212) 271-4880
Whitefort Capital Master Fund, LP (Filed by) CIK: 0001704387 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SC 13D/A